Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights NEW YORK and CLEVELAND, March 31, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical  company  focused  on  developing...

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa Abeona’s Fourth Gene Therapy Program to Receive EMA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in...